NCT00413972已完成3 期
A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Groups Study Comparing the Efficacy and Safety of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 392
- 主要终点
- Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment
研究概览
简要总结
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 3 study of Vytorin 10/10 (ezetimibe 10 mg with simvastatin 10 mg), Vytorin 10/20 (ezetimibe 10 mg with simvastatin 20 mg), and Vytorin 10/40 (ezetimibe 10 mg with simvastatin 40 mg) compared to placebo administered daily for 8 consecutive weeks in subjects with primary hypercholesterolemia (LDL-C >3.64 mmol/L [140 mg/dL]). The efficacy of daily Vytorin versus placebo in reducing the concentration of LDL-C will be evaluated, and the efficacy of daily Vytorin versus placebo with respect to change in the concentrations of total cholesterol, triglycerides, and HDL-C will be compared. The safety of Vytorin versus placebo will also be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must be >=18 years and <=75 years of age, male or female.
- •Primary hypercholesterolemic subject with a plasma LDL cholesterol concentration >3.64 mmol/L (140 mg/dL) to <=6.3 mmol/L (250 mg/dL) using the Friedewald calculation; total cholesterol (TC) >5.2 mmol/L (200 mg/dL) to <12.7 mmol/L (500 mg/dL) and triglyceride concentrations of <=3.99 mmol/L (350 mg/dL) should be met at the same time. At the time of recruitment (Visit 1), these values may be lower if the subject is on lipid-lowering therapy. (ie, prior to the start of lipid lowering drug washout) or may be higher at the start of dietary therapy.
- •Liver transaminases (ALT, AST) <=50% above the upper limit of normal, with no active liver disease and CK <=50% above the upper limit of normal.
- •Clinical laboratory tests (complete blood count [CBC], blood chemistries, urinalysis) must be within normal limits, or clinically acceptable to the investigator/sponsor.
- •Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control.
- •Subjects must be free of any clinically significant diseases other than hyperlipidemia that would interfere with study evaluations.
- •Subjects must understand and be able to adhere to the dosing and visit schedules.
- •Subject must agree to remain on a cholesterol-lowering diet for the duration of the study (according to China Adult Treatment Panel of High Blood Cholesterol).
排除标准
- •Subjects whose body mass index (BMI=weight [kg]/height2 [m]) is >=30 kg/m2 at Visit 3 (Baseline Visit).
- •Subjects who have known hypersensitivity to HMG CoA reductase inhibitors.
- •Subjects who consume >14 alcoholic drinks per week. (A drink is: a can of beer, glass of wine, or single measure of spirits).
- •Any condition or situation, which in the opinion of the investigator, might pose a risk to the subject or interfere with participation in the study.
- •Women who are pregnant or nursing.
- •Subjects who have not observed the designated washout periods for any of the prohibited medications.
- •Congestive heart failure defined by NYHA as Class III or IV.
- •Uncontrolled cardiac arrhythmia.
- •Myocardial infarction, coronary bypass surgery, or angioplasty within 6 months of study entry.
- •Unstable or severe peripheral artery disease within 3 months of study entry.
- •Unstable angina pectoris within 6 months of study entry.
- •Uncontrolled hypertension (treated or untreated) with systolic blood pressure >160 mm Hg or diastolic >100 mm Hg at study entry.
- •Uncontrolled (as determined by fasting glucose >180 mg/mL or HbA1c >9%) or newly diagnosed (within 1 month of study entry) diabetes mellitus.
- •Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins, ie, secondary causes of hyperlipidemia, such as secondary hypercholesterolemia due to hypothyroidism (thyroid stimulating hormone [TSH] above upper limit of normal). Subjects with a history of hypothyroidism who are on a stable therapy of thyroid hormone replacement for at least 6 weeks are eligible for enrollment if TSH levels are within normal limits before enrollment.
- •Known impaired renal function (plasma creatinine >2.0 mg/dL), or nephrotic syndrome at study entry.
- •Disorders of the hematologic, digestive, or central nervous systems, including cerebrovascular disease and degenerative disease that would limit study evaluation or participation.
- •Known HIV positive.
- •Cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas).
- •History of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy.
- •Female subject receiving hormonal therapy, including hormone replacement, any estrogen antagonist/agonist, or oral contraceptives.
研究组 & 干预措施
Vytorin 10/10
Experimental
Ezetimibe 10 mg with Simvastatin 10 mg
干预措施: Ezetimibe with Simvastatin (Drug)
Vytorin 10/20
Experimental
Ezetimibe 10 mg with Simvastatin 20 mg
干预措施: Ezetimibe with Simvastatin (Drug)
Vytorin 10/40
Experimental
Ezetimibe 10 mg with Simvastatin 40 mg
干预措施: Ezetimibe with Simvastatin (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment
时间窗: Baseline, 8 weeks
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
A Study of TG103 Injection in Non-diabetic Overweight or ObesityOverweight or ObesityNCT05997576CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.675
招募中
3 期
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable AnginaChronic Stable Angina PectorisNCT03789552Tasly Pharmaceuticals, Inc.765
进行中（未招募）
3 期
A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT06258148CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.465
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With IvacaftorCystic FibrosisNCT02347657Vertex Pharmaceuticals Incorporated510
Unknown
3 期
Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminType 2 Diabetes MellitusNCT02477969Jiangsu Hansoh Pharmaceutical Co., Ltd.587